



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

August 7, 2021

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, For,
Mumbai 400001

Scrip Code: 524816

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza, Bandra Kurla Complex
Bandra East, **Mumbai 400051**

Scrip Code: NATCOPHARM

Dear Sir

Sub: - Q1 FY22 Financial Results Earnings Call

The Company will host an Earnings Call with Investors / Analysts at **on Thursday, August 12, 2021, at 6:00 PM IST** to disseminate Financial Results of the company for the Q1 FY22 ending June 30, 2021.

A Copy of the same is enclosed for your ready reference

Thanking you

Yours faithfully
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)



Investec India invites you to
Natco Pharma
Q1 FY22 Earnings call



Q1 FY22 Earnings Call Thursday, August 12, 2021 6:00 pm IST	Diamond Pass Registration
Management Team	
Mr. Rajeev Nannapaneni Vice Chairman & Chief Executive Officer	Mr. Rajesh Chebiam VP-Acquisitions, Institutional Investor Management & Corporate Communications
Dial-In Numbers	
Universal Dial-In (+91 22 6280 1245) / (+91 22 7115 8146)	International Toll Free Hong Kong (800964448) Singapore (8001012045) UK (08081011573) USA (18667462133)
For further information please contact:	
Anshuman Gupta (+9122 6849 7440) Anshuman.gupta@investec.co.in	Swapna Bhandarkar (+9122 6849 7472) swapna.bhandarkar@investec.com



Investec Bank plc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Registered in England and Wales (No. 489604). Registered office at 30 Gresham St, London EC2V 7QP.